BRIEF published on 04/28/2026 at 20:40, 4 months 12 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 4 months 12 days ago GenSight Biologics annonce son Assemblée Générale Mixte de 2026 Actionnaires Assemblée Générale Documents Préparatoires Thérapie Génique GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 4 months 12 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
BRIEF published on 04/28/2026 at 20:40, 4 months 12 days ago GenSight Biologics programme son assemblée générale annuelle pour mai 2026 Conformité Réglementaire Assemblée Générale Annuelle Thérapie Génique Relations Avec Les Investisseurs Informations Destinées Aux Actionnaires
PRESS RELEASE published on 04/28/2026 at 20:35, 4 months 12 days ago Informations privilégiées / Autres communiqués GenSight Biologics annonce sa prochaine Assemblée Générale Mixte du 19 mai 2026 avec mise à disposition des documents préparatoires. Informations complètes disponibles sur le site de la Société Documents Préparatoires Assemblée Générale Mixte GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
PRESS RELEASE published on 04/28/2026 at 20:35, 4 months 12 days ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 19, 2026, in Paris. Shareholders can access preparatory documents online. Meeting details and documents available on company website Annual General Meeting Shareholders Preparatory Documents Meeting Details GenSight Biologics
BRIEF published on 04/07/2026 at 19:04, 5 months 3 days ago GenSight Biologics fait le point sur sa trésorerie et ses revenus liés à l'accès anticipé. Thérapie Génique GenSight Biologics Revenu Programme D'accès Anticipé Position De Trésorerie
BRIEF published on 04/07/2026 at 19:04, 5 months 3 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
BRIEF published on 04/07/2026 at 19:04, 5 months 3 days ago GenSight Biologics : Bilan financier et avancées sur l'AAC Trésorerie Levée De Fonds Thérapie Génique GenSight Biologics Accès Compassionnel
BRIEF published on 04/07/2026 at 19:04, 5 months 3 days ago GenSight Biologics: Financial Update and Progress on AAC Fundraising Treasury Gene Therapy GenSight Biologics Compassionate Access
Published on 09/10/2026 at 22:25, 3 hours 37 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 10 hours 42 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 11 hours 2 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 11 hours 25 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 1 hour 57 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 3 hours 22 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 3 hours 51 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 3 hours 55 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 6 hours 32 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 6 hours 32 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 7 hours 52 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 8 hours 17 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 8 hours 19 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
